SEC 13F Intelligence

Trails Edge Capital Partners, LP / ACAD

Trails Edge Capital Partners, LP’s Acadia Pharmaceuticals Inc Position

Does Trails Edge Capital Partners, LP own Acadia Pharmaceuticals Inc (ACAD)? Not currently — the last reported position was 1.42M shares worth $38M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$38M
Q4 2025
Shares
1.42M
% of Portfolio
+9.37%
Quarters Held
1
position exited

Position History ACAD

Reported value by quarter
Q4 ’25: $38MQ4 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q4 20251.42M$38M+9.37%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Trails Edge Capital Partners, LP’s full portfolio or all institutional holders of ACAD.